Uppsala, Sweden – March 31, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today, the last trading day of the month, there are in total 37,156,639 shares in Orexo - whereof 35,127,056 are ordinary shares with one vote per share and 2,029,583 are class C shares with one tenth of a vote per share. The total number of votes in the company is 35,330,014.3.

The change follows the conversion of Class C shares into ordinary shares, as announced on 19 February 2026.

For more information contact
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.

For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
 

This information is information that Orexo AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-03-31 17:30 CEST.

Attachments
Number of shares and votes in Orexo